- Conditions
- Breast Carcinoma
- Interventions
- Decision Aid, Discussion, Questionnaire Administration
- Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 22,526
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Angiosarcoma
- Interventions
- TRC105, Votrient
- Biological · Drug
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Palo Alto, California • Santa Monica, California + 22 more
- Conditions
- Vitamin D Deficiency
- Interventions
- Placebo, 800 IU/day vitamin D supplementation with feedings in the first 28 days after birth, Usual Care
- Dietary Supplement · Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 24 Hours to 96 Hours
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Renal Cell Carcinoma, Kidney Cancer
- Interventions
- Capecitabine, Gemcitabine, Bevacizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastric Cancer, Non-Atrophic Gastritis, Intestinal Metaplasia
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 7
- States / cities
- Batesville, Arkansas • Stanford, California • Athens, Georgia + 4 more
- Conditions
- Lung Cancer
- Interventions
- Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Surgical Site Infection
- Interventions
- Ertapenem, Cefazolin and Metronidazole.
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Psoriasis Vulgaris
- Interventions
- LEO 90100, Calcipotriol, Betamethasone
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 33
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 26 more
- Conditions
- Physiological and Psychological Responses to Exercise
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- University of Houston
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Skin Cancer
- Interventions
- Part 1: Interview + Questionnaires, Part 2: Multiple Questionnaires
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more
- Conditions
- Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory
- Interventions
- Mogamulizumab
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Stanford, California + 4 more
- Conditions
- Erosive Esophagitis
- Interventions
- BLI5100, PPI Control
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 122
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Peoria, Arizona + 99 more
- Conditions
- Leukemia
- Interventions
- BKM120
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypertension
- Interventions
- Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo
- Drug
- Lead sponsor
- George Medicines PTY Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more
- Conditions
- Advanced Solid Tumor
- Interventions
- BG-75098, BGB-43395, Fulvestrant
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Duarte, California • New Haven, Connecticut + 4 more
- Conditions
- Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Methotrexate, Doxorubicin, Thioguanine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Interventions
- ARX788
- Drug
- Lead sponsor
- Ambrx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more
- Conditions
- Major Depressive Disorder
- Interventions
- SP-624, Placebo
- Drug
- Lead sponsor
- Sirtsei Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 36 more
- Conditions
- Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash
- Drug · Other
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 890 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
- Conditions
- HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
- Interventions
- PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
- Conditions
- Pigmented Villonodular Synovitis, TGCT, Tenosynovial Giant Cell Tumor
- Interventions
- AMB-05X
- Biological
- Lead sponsor
- AmMax Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Sacramento, California • Miami, Florida • Houston, Texas
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer
- Interventions
- ATX-559
- Drug
- Lead sponsor
- Accent Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more
- Conditions
- Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas
- Interventions
- Imatinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Tampa, Florida • Chicago, Illinois + 2 more